Navigation Links
The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
Date:8/25/2008

Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.

Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are extremely encouraged by the results of the AZA-001 trial which for the first time showed that survival could be extended for patients with higher-risk MDS," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML), but treatment with VIDAZA significantly delays this progression. VIDAZA not only has great survival data in MDS, but can also prevent progression to AML."

Results from the trial also showed that azacitidine reduced the need for blood transfusions in higher-risk MDS patients with nearly half (45 percent) of patients who were transfusion dependent at the start of the trial achieving transfusion independence.

Additionally, azacitidine was shown to delay the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells, either red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
800-637-0839
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference
2. Michael J. Fox Foundation PD Therapeutics Conference
3. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
4. W.M. Keck Foundation grant funds reproductive science research
5. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
6. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
7. Glenn Foundation for Medical Research commits $5 million to study aging
8. BBVA Foundation Awards for Biodiversity Conservation
9. The Parkinsons Disease Foundation awards $950,000 in seed grants
10. The AGA Foundation invests in gastroenterologys future
11. European Science Foundation aims to strengthen regenerative medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... ... , ... Kapstone Medical is proud to announce that it has ... and inventors develop and safeguard their latest innovations. The company has grown from ... of clients in the United States and around the world. , Company Founder ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is ... for analytical and scientific instruments. This year’s symposium, organized by the Pittcon 2018 ... Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... of 6” modular downlights designed to stay tightly sealed and perform efficiently for ... damp and wet location listings just aren't enough, such as: hospitals; behavioral health ...
(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica accounts ... and abiotic factors. During this educational webinar, participants will learn about the importance ... gain a better understanding of how genomics is important for coffee breeding improvement. ...
Breaking Biology Technology: